Who Is Brez? A Brand File on the Viral THC + Lion's Mane Social Tonic

Brez is a marketing-led success with a transparency gap underneath it. The product is real and well-liked, the founder is public, and the growth is documented — all genuine positives that keep this from scoring lower. But our score measures what you can verify and how a company treats its customers, and on both fronts Brez has soft spots: lab reports that are hard to find and skew potency-only, a manufacturer it never named on its own, and a live dispute over its subscription billing.

We'll separate sourced fact (the Florida LLC, the named founder, the co-packer, the BBB rating, the class action) from marketing (the "GMP," the "#1 social tonic" framing), and we'll credit the things Brez actually does well rather than pretend the popularity isn't earned.

Unlike a lot of the opaque operators in these files, Brez doesn't hide its founder. The operating entity is Drink Brez LLC, a Florida limited liability company based in West Palm Beach, founded in 2023, and it's led publicly by founder and CEO Aaron Nosbisch — a named, findable person with a documented marketing background (he previously ran a cannabis-focused social-advertising agency). That alone earns Brez real credit; compare it to Exhale Wellness, which won't even print its founders' last names.

Brez is a beverage brand, not a beverage manufacturer — which is completely normal. What's notable is how we learned who actually makes it. Brez's own materials say the drink is "crafted in small batches" in Florida, but they don't name the co-packer. The specific manufacturer — a Sarasota, Florida beverage formulator — became public not through Brez's disclosure but through a California Proposition 65 legal notice, which named both Brez as distributor and the contract manufacturer by name.

On quality systems, Brez (via secondary reviews) is described as using "GMP-registered facilities," but we found no published certificate, registration number, or auditor, and no FDA facility registration on record. As with a lot here, the reassuring word is present; the verifiable proof behind it isn't. Naming your maker and your certification is a basic transparency bar, and Brez clears it only reluctantly and partially.

Brez does publish Certificates of Analysis, which is to its credit. But the disclosure has three problems that hold the safety pillar down:

• They're hard to find. The COAs live on a footer-buried /pages/labs page rather than being linked from each product; common URLs like /coa or /lab-results just 404.
• The lab keeps changing. Batch reports trace to several different labs across products, with no single named, accredited partner stated in plain text — which makes the testing harder to assess as a consistent program.
• They skew potency-only. The reports we could view emphasized the cannabinoid potency panel; a complete, readable contaminant panel (heavy metals, pesticides, microbials, solvents) for a given batch wasn't clearly verifiable. The marketing says "tested for contaminants"; the posted document doesn't always show it.

Compare that to 3Chi or TRE House, which put batch-specific, full-panel reports from named, ISO-accredited labs a click away. "We test, somewhere, by someone, mostly for potency" is a meaningfully weaker assurance for something you drink.

Here's where Brez looks good. By its own (unaudited) account it bootstrapped to profitability within months and grew fast — self-reported revenue in the tens of millions — before opening its first outside raise in 2025 through a special-purpose vehicle (an accredited-investor structure), reported in trade press at a post-money valuation around the mid-nine figures. The specific investors aren't named, and the figures are self-reported, so we treat them as directional rather than gospel. But the arc — founder-funded, profitable, then a priced outside raise — is documented and credible, and it's a healthier story than the unverifiable "we're #1" claims many brands lean on.

We found no credible, sourced evidence of any foreign ownership or funding, and we don't insinuate any — the cap table simply isn't fully public, which is ordinary for a private company at this stage.

Brez's reputation is mostly positive — an A+ BBB rating (though not accredited), thousands of favorable on-site and social reviews, and no FDA warning letter or recall that we could find. That real customer enthusiasm is why this is a D and not lower.

In our view, Brez is a genuinely good product wrapped in great marketing and thinner-than-it-looks accountability. The founder is public, the company is real and growing, and the per-serving dosing is honest — all things we credit. But if you want to verify the lab testing or trust the billing, Brez asks you to work harder than a top-tier brand should make you, and the subscription dispute is a real flag. That mix — likable and legitimate, but soft on verification — is exactly what a D captures.

If you buy Brez, our practical advice: buy single packs rather than enrolling in the subscription until the auto-renewal questions are resolved, and pull the COA for your specific batch (accepting that you may not get a full contaminant panel or a consistent lab). A D (60/100) — viral, founder-led, and still maturing on the fundamentals. The full methodology shows every point; if Brez names a consistent accredited lab, publishes full-panel COAs per batch, and resolves the subscription issues, we'll update the file (see the notice below).